Pet food mouldings from popcorn with low caloric value.

Written by Dr. Stefan Uhle on 07 September 2020.

Pet food mouldings for dogs and cats with excellent taste and low caloric value

The present invention relates to a method for producing dry pet food articles from puffed corn in all kinds of shapes and forms with good taste and low caloric value.

New therapeutic target against bacterial or viral infections

Written by Dr. Stefan Uhle on 07 September 2020.

New therapeutic target against bacterial or viral infections

Targeting key proteins in viral or bacterial pathogens is an appealing way to combat infectious diseases. A new protein domain has been discovered as a therapeutic target.

Reducing mortality after Aortic-Valve Implantation

Written by Dr. Martin Andresen on 07 September 2020.

Reducing the mortality rate of patients after Aortic-Valve Implantation by Anti-Fibrotic Treatment

A subpopulation of patients with a very high rist to die in only one year after an aortic valve implantation (AVI) was identified. A novel treatment may save lives by analysing the level of fibrosis in the heart tissue.

GMP-compatible methods for producing tissue-engineered human heart muscle from stem cells

Written by Dr. Jens-Peter Horst on 22 January 2020.

GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells

Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional cell structure from cardiomyocytes or directly from progenitor cells. Scientists at the University of Göttingen developed two new and fully defined methods for serum-free production of engineered human heart muscles.

EYA1— Biomarker and Target for kidney fibrosis

Written by Dr. Vanessa Jensen on 20 January 2020.

EYA1 — Biomarker and therapeutic target for kidney fibrosis

The EYA1 splicing was found to be linked with the progression of fibrosis. Patients expressing predominantly EYA1-A ("bad" variant) end up in the end stage renal disease earlier and suffer from a higher mortality. A shift of splicing towards EYA1-C ("good" variant) effectively attenuates fibrosis in vivo (mouse model).